New 'Living Drug' trial aims to tame rogue immune system
NCT ID NCT07502859
Summary
This is an early-stage study to test the safety and initial effects of a new cell therapy called BEN301 Injection for people with certain autoimmune diseases. The therapy involves modifying a patient's own immune cells (called CAR-Tregs) to try to calm down the overactive immune system that causes conditions like scleroderma and rheumatoid arthritis. The study will enroll 24 adults to find a safe dose and look for early signs that it might help control their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSC RA SS IIM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boren Hospital, Beijing.
Beijing, Beijing Municipality, 100070, China
Conditions
Explore the condition pages connected to this study.